Inovio Pharmaceuticals, Inc. has announced the suspension and termination of its at-the-market (ATM) prospectus, which was originally dated August 13, 2024. This decision was communicated to Oppenheimer & Co. Inc., the sales agent involved in the sales agreement. The company will not proceed with any sales of its common stock under this agreement until a new prospectus is filed. As of April 1, 2026, Inovio had issued and sold a total of 1,319,644 shares of its common stock under the ATM offering program, generating gross proceeds of approximately $3.2 million before deducting sales commissions and offering expenses. The sales agreement remains in effect despite the suspension of the prospectus. This move is seen as a precautionary measure, reflecting the company's current strategic focus and market conditions. Investors will be closely monitoring Inovio's next steps regarding its capital raising efforts and any potential impacts on its liquidity and operational strategies.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.